GlobeNewswire Inc.··NaMannKind to Present at Oppenheimer Conference While Advancing Pediatric Diabetes Program
MannKind's CEO will present at Oppenheimer Conference on February 26 while the company enrolls first patient in pediatric diabetes trial for its Afrezza insulin therapy.
MNKDQ4 2025 financial resultsbiopharmaceutical